Kintara CEO Robert Hoffman and CSO Dennis Brown will participate in a fireside chat at the Maxim Group Virtual #Healthcare Conference on Tuesday, June 20.
Learn more: bit.ly/4468qKA
$KTRA #KTRA
Follow
Kintara Therapeutics, Inc. NASDAQ: KTRA
@Kintara_Thera
Our Fight Against Cancer: Kintara Therapeutics is dedicated to the development of novel cancer therapies.
NASDAQ: KTRA
Kintara Therapeutics, Inc. NASDAQ: KTRA’s Tweets
In addition to #glioblastoma, data supports the therapeutic potential of our lead asset in #pediatric brain tumors and #OvarianCancer.
Learn more about VAL-083: bit.ly/3HzzFoE
$KTRA #KTRA
4
Kintara CSO Dennis Brown spoke with about the role of China-based CDMOs for US-based drug developers.
Read the full article: bit.ly/4605Ebv
$KTRA #KTRA
2
Kintara is evaluating VAL-083 in patients with #glioblastoma, an aggressive form of #BrainTumor.
Visit to learn how you can support patients this Brain Tumor Awareness Day: bit.ly/3Cj5UVv
$KTRA #KTRA
2
5
As #CancerResearchMonth comes to a close, we celebrate the incredible success stories that have been made possible in part by innovative #DrugDevelopment.
Learn more from : bit.ly/3vi4UhP
#NCRM23 $KTRA #KTRA
4
Kintara’s mission is to unleash the power of #biology to fight #cancer and identify opportunities where our investigational treatments can improve patient survival and quality of life.
Learn more about our approach to #DrugDevelopment: bit.ly/3HzzFoE
$KTRA #KTRA
1
3
Kintara CSO Dennis Brown recently sat down with to discuss his career in developing anticancer small molecules and the role of outsourcing in #DrugDevelopment.
Read: bit.ly/3IsR6aw
$KTRA #KTRA
1
4
The Kintara team was honored to ring the #ClosingBell today alongside and in commemoration of National #BrainTumor Awareness Month. #GoGrayinMay
Learn more about our work: bit.ly/3Wmxc6G
$KTRA #KTRA
2
11
This week is #WomensHealthWeek. Kintara is evaluating VAL-083 in #OvarianCancer, a disease which is diagnosed in nearly 20,000 American women yearly.
Learn more: bit.ly/423n3NZ
$KTRA #KTRA
1
3
Today Kintara announced third quarter financial results and provided a corporate update.
See the news release: bit.ly/41nsnLi
$KTRA #KTRA
2
Kintara CEO Robert Hoffman will present a corporate overview at the Micro-Cap Virtual Conference on Wednesday at 4pm ET.
More details: bit.ly/3nFspQW
$KTRA #KTRA
1
4
Kintara is committed to researching and developing unique anti-cancer compounds.
This #CancerResearchMonth, learn about the important role of research in developing new treatments, from : bit.ly/3vi4UhP
#NCRM23 $KTRA #KTRA
3
4
Initial #tumor response rates for #OvarianCancer patients under current standard of care are relatively high, but relapse remains a significant threat.
Learn more about the need for novel treatments: bit.ly/423n3NZ
$KTRA #KTRA
2
Kintara’s research has demonstrated promising pre-clinical results for the treatment of #pediatric #BrainTumors with VAL-083. In prior clinical trials, VAL-083 demonstrated activity against pediatric brain cancers.
Learn more: bit.ly/3L5VXij
$KTRA #KTRA
1
5
#ICYMI – Kintara’s #AACR23 poster presentations are now available on our website.
Learn more about the latest data supporting VAL-083: bit.ly/3A5iE10
$KTRA #KTRA
1
5
7
Kintara will present two posters at #AACR23, which will include data from our VAL-083 program for the treatment of recurrent #glioblastoma. Attendees can see our posters on Monday 4/17 from 1:30-5pm ET in Poster Section 34.
More info: bit.ly/3H7upbh
$KTRA #KTRA
2
3
#ICYMI – CEO Robert Hoffman sat down with on the #EmpoweredPatient podcast to explain the benefits of VAL-083’s unique mechanism of action.
Listen: bit.ly/3Zw4yR1
$KTRA #KTRA
3
VAL-083 has a unique structure that provides many benefits, including the targeting of DNA for its therapeutic effect and its ability to cross the blood brain barrier. These characteristics increase its potential to treat various #cancers.
bit.ly/3FOWvY0
$KTRA #KTRA
4
While Glioblastomas are a common form of #BrainCancer, the prevalence of the disease differs largely between men and women.
Learn more about the incidence of #Glioblastoma: bit.ly/3F91D94
$KTRA #KTRA
2
2
#ICYMI – CEO Robert Hoffman was featured on where he discussed the #ClinicalTrial for Kintara’s lead therapeutic candidate, VAL-083, which is currently being evaluated in patients with #Glioblastoma Multiforme.
Listen: bit.ly/3G5i1aW
#GBM
2
2
Because it’s a #brain tumor, #Glioblastoma Multiforme presents unique treatment challenges compared to other #cancers.
Learn more about the unmet needs of #GBM patients from : bit.ly/3RlY2aM
2
Kintara Therapeutics is focused on developing anti-cancer compounds for indications where patients are failing to tolerate current therapies.
Learn more about our #pipeline: bit.ly/3FOWvY0
#Cancer #Oncology
2
Kintara CEO Robert Hoffman weighs in on #biopharma industry trends and expectations for the year ahead in .
Read more #ClinicalTrial trend predictions from Robert and other industry leaders: bit.ly/3Zsj6Br
1
5
Kintara will present two posters at #AACR23, which will include data from our VAL-083 program for the treatment of recurrent #glioblastoma.
Learn more: bit.ly/406AYBM
1
2
3
This month, Kintara will participate in the annual #ROTH conference and the annual Glioblastoma Drug Development Summit (@GMPSummit).
See the presentation details here: bit.ly/3JvtHG7
1
3
Despite the existence of current treatments, the survival rate for #Glioblastoma Multiforme patients remains low.
Learn how Kintara is working to develop VAL-083 to improve #GMB patient outcomes: bit.ly/3F91D94
2
3
CFO Scott Praill reflected on Kintara’s strategy for #fundraising in the current biopharma market and key strategies used at #BIOCEO.
Read in :
1
4
#ICYMI – CEO Robert Hoffman sat down with on the #EmpoweredPatient podcast to discuss the current therapeutic landscape for #glioblastoma multiforme.
Listen: bit.ly/3Zw4yR1
3
3
Our research supports VAL-083’s potential as a new therapeutic option for platinum-resistant #OvarianCancer patients whose treatment is underserved by currently available therapy.
Learn more: bit.ly/3HzzFoE
#Cancer #Oncology
1
8
VAL-083 (dianhydrogalactitol) is Kintara’s investigational therapy for the treatment of #glioblastoma multiforme (#GMB).
Read more about our #ClinicalDevelopment of VAL-083 in : bit.ly/3ISEtGp
1
4
This month, join us in supporting #cancer prevention research and helping to educate others about critical risk factors.
Learn more about #CancerPreventionMonth from : bit.ly/3IMn1jI
2
5
Recurrence is common among #Glioblastoma Multiforme patients treated with currently approved therapies, signaling the need for more effective options.
Learn more about Kintara’s investigational therapy for #GMB: bit.ly/3HzzFoE
1
4
Kintara is dedicated to the development of novel #cancer therapies for patients who are failing or resistant to current treatment regimens.
Learn how you can support people living with cancer this #WorldCancerDay: bit.ly/2C4bCMA
2
3
Kintara CEO Robert Hoffman will present a corporate overview and recent company highlights at #BIOCEO.
Join us on 2/6 at 4:30pm ET: prn.to/3DsvF6E
1
4
6
By developing VAL-083, Kintara seeks to offer new treatment options for conditions where patients are unable to tolerate current therapies.
Learn more about the science supporting VAL-083: bit.ly/3HzzFoE
#GMB #OvarianCancer
2
5
1
5
We are excited to announce the opening of a second site in Europe: Universitätsspital Basel
is now recruiting patients for #GBMAGILE! 🥳
👏Site PI: Dr. Heinz Läubli
🧠 GBM AGILE is a clinical trial for patients with #glioblastoma
To learn more, visit: gcaresearch.org/gbm-agile/abou
5
17
UCSF Brain Tumor Center: Glioblastoma is a highly malignant brain tumor that arises from astrocytes, the supportive cells in the nervous system.
braintumorcenter.ucsf.edu/condition/glio
#GBM #Glioblastoma #malignantbraintumor #cancer
2
2
7
Learn more about how the data generated by #GBMAGILE speeds the process of getting new treatments to patients with #glioblastoma, all while enabling future discoveries in clinical research.
Video featuring
7
15